Nevro Corp. (NYSE:NVRO) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP decreased its stake in Nevro Corp. (NYSE:NVRO - Free Report) by 33.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 220,469 shares of the medical equipment provider's stock after selling 108,604 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.60% of Nevro worth $1,856,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Goldman Sachs Group Inc. grew its position in shares of Nevro by 69.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,048,026 shares of the medical equipment provider's stock worth $22,554,000 after purchasing an additional 431,136 shares in the last quarter. Assenagon Asset Management S.A. grew its position in shares of Nevro by 490.7% during the second quarter. Assenagon Asset Management S.A. now owns 728,463 shares of the medical equipment provider's stock worth $6,134,000 after purchasing an additional 605,134 shares in the last quarter. Acadian Asset Management LLC grew its position in shares of Nevro by 154.1% during the second quarter. Acadian Asset Management LLC now owns 241,186 shares of the medical equipment provider's stock worth $2,029,000 after purchasing an additional 146,276 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Nevro by 7.3% during the second quarter. Bank of New York Mellon Corp now owns 127,866 shares of the medical equipment provider's stock worth $1,077,000 after purchasing an additional 8,673 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new stake in shares of Nevro during the first quarter worth about $1,446,000. Hedge funds and other institutional investors own 95.52% of the company's stock.

Analyst Ratings Changes

NVRO has been the subject of a number of research reports. Wolfe Research raised Nevro from an "underperform" rating to a "peer perform" rating in a research note on Thursday, August 8th. JMP Securities cut Nevro from an "outperform" rating to a "market perform" rating in a report on Wednesday, August 7th. StockNews.com upgraded Nevro from a "sell" rating to a "hold" rating in a report on Monday, September 30th. Morgan Stanley decreased their target price on Nevro from $14.00 to $9.00 and set an "equal weight" rating for the company in a research report on Monday, July 15th. Finally, Royal Bank of Canada decreased their target price on Nevro from $16.00 to $7.00 and set a "sector perform" rating for the company in a research report on Wednesday, August 7th. Three research analysts have rated the stock with a sell rating and twelve have assigned a hold rating to the company. According to data from MarketBeat.com, Nevro has a consensus rating of "Hold" and an average price target of $10.55.

Nevro Stock Up 4.8 %

NYSE:NVRO traded up $0.22 during mid-day trading on Friday, hitting $4.83. 296,133 shares of the company's stock traded hands, compared to its average volume of 563,737. The company has a fifty day moving average of $5.56 and a 200 day moving average of $8.70. Nevro Corp. has a twelve month low of $4.38 and a twelve month high of $22.64. The company has a market capitalization of $177.40 million, a P/E ratio of -2.11 and a beta of 0.94. The company has a debt-to-equity ratio of 0.66, a quick ratio of 3.53 and a current ratio of 4.77.

Nevro (NYSE:NVRO - Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.10. Nevro had a negative return on equity of 24.89% and a negative net margin of 18.17%. The business had revenue of $104.16 million for the quarter, compared to the consensus estimate of $107.11 million. During the same quarter in the previous year, the business earned ($0.69) EPS. The company's quarterly revenue was down 4.3% compared to the same quarter last year. On average, analysts forecast that Nevro Corp. will post -2.6 EPS for the current year.

Nevro Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.